Strand Life Sciences, a subsidiary of Reliance Industries and a global leader in genomic and bioinformatic solutions, has introduced its cutting-edge prenatal screening and diagnostics portfolio, customized for the Indian population.

The pioneering portfolio includes two revolutionary technologies: CNSeq and MaatriSeq, meticulously crafted to address the specific requirements of Indian communities.

These groundbreaking technologies offer unparalleled efficiency, affordability, and precision, revolutionizing genetic diagnostics in India, according to the company.

Developed by Strand Life Sciences, these advanced tests are based on a genomic analysis pipeline meticulously validated on Indian samples and conditions, ensuring accuracy and reliability.

Ramesh Hariharan, CEO & co-founder of Strand Life Sciences, emphasized the company's commitment to setting new benchmarks in genetic diagnostics. He stated, "Strand is leading the charge in advanced genomic solutions, redefining the standards in genetic diagnostics."

Hariharan expressed Strand's dedication to supporting the Indian government's initiatives to alleviate the burden of rare diseases in the country.

Key Features of Prenatal Screening & Diagnostics Technologies

CNSeq represents a significant leap forward in prenatal diagnostics, leveraging state-of-the-art Next Generation Sequencing technology. Powered by proprietary software, CNSeq delivers unparalleled precision in identifying Copy Number Variations (CNVs), surpassing conventional cytogenetic and molecular techniques.

In contrast, MaatriSeq stands out as the first Non-Invasive Prenatal Screening (NIPS) solution validated on the Illumina NovaSeq X Plus sequencing platform. This technology offers a highly accurate and cost-effective alternative, facilitating widespread access to prenatal screening across India. Demonstrating exceptional sensitivity and specificity, MaatriSeq excels in identifying fetal chromosomal abnormalities, outperforming existing methods.